10x Genomics, Inc.

NasdaqGS:TXG Voorraadrapport

Marktkapitalisatie: US$2.8b

10x Genomics Beheer

Beheer criteriumcontroles 4/4

De CEO 10x Genomics is Serge Saxonov, benoemd in Jul2012, heeft een ambtstermijn van 13.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.33M, bestaande uit 10.7% salaris en 89.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.26% van de aandelen van het bedrijf, ter waarde $ 91.69M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 6.9 jaar.

Belangrijke informatie

Serge Saxonov

Algemeen directeur

US$6.3m

Totale compensatie

Percentage CEO-salaris10.65%
Dienstverband CEO13.8yrs
Eigendom CEO3.3%
Management gemiddelde ambtstermijn2.3yrs
Gemiddelde ambtstermijn bestuur6.9yrs

Recente managementupdates

Recent updates

TXG: Spatial Consumables Strength Will Offset Instrument Softness In 2026

The analyst price target for 10x Genomics has shifted from about $24 to $32, with analysts pointing to recent target hikes across multiple firms that reflect updated views on product adoption, competitive positioning in single cell, and mixed trends across instrument and consumables demand. Analyst Commentary Recent research shows a cluster of bullish analysts increasing their price targets on 10x Genomics, as well as at least one upgrade, pointing to a more constructive stance on the story.

TXG: Spatial Consumables And New Product Uptake Will Shape 2026 Outlook

Analysts have raised their average price target on 10x Genomics from about $18 to roughly $24, citing solid new product adoption, a favorable competitive setup in single cell, and expectations that pressure in instruments and single cell consumables could be partly offset by growth in spatial consumables. Analyst Commentary Recent research updates show a cluster of bullish analysts lifting price targets on 10x Genomics, with new targets cited at about $18, $20 and $25.

10x Genomics: Undervalued Amid Consumables-Led Transition

Mar 24

TXG: New Product Uptake And Funding Uncertainty Will Shape 2026 Setup

Analysts have nudged the blended price target for 10x Genomics higher, with recent moves such as Stifel lifting its target to $25 from $20 and UBS taking its target to $20 from $14, citing solid new product adoption, a favorable single cell competitive setup, and mixed but evolving trends in academic funding, instruments, and consumables. Analyst Commentary Recent research points to a more balanced view on 10x Genomics, with higher price targets reflecting confidence in certain growth drivers alongside caution around funding visibility and product mix.

TXG: 2026 Academic Weakness And Pricing Pressure Will Test Elevated Expectations

Analysts have inched up their price targets on 10x Genomics, with moves such as $14 to $20 at UBS, $15 to $18 at TD Cowen and $20 to $25 at Stifel. These changes reflect a mix of confidence in new product adoption, a favorable single cell competitive setup, and expectations that spatial consumables can help offset pressure in single cell consumables and softer academic instrument demand.

TXG: 2026 Academic Demand And Pricing Pressures Will Challenge Rich Sentiment

The analyst price target for 10x Genomics has increased from $14 to $17, as analysts factor in updated assumptions for faster revenue growth, slightly higher margins, and a higher future P/E multiple, despite ongoing caution around academic demand and single cell consumables. Analyst Commentary Recent street research on 10x Genomics points to a mixed setup, with price target changes reflecting both interest in the story and clear caution around execution, product mix, and end market trends.

TXG: Higher Q4 Bar And Soft 2026 Setup May Cap Upside

Analysts have nudged their price target on 10x Genomics up to $18 from $15, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that they view as better aligned with their latest outlook on the life science tools space. Analyst Commentary Recent research points to a more balanced stance on 10x Genomics, with the higher price target reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E while the rating remains neutral.

10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Jan 24
10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

TXG: ARK Buying And Soft 2026 Outlook Will Restrain Upside Potential

Analysts have nudged their 10x Genomics price target higher to about $18, up from around $17.36. This reflects slightly updated fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, alongside recent Street research that includes an $18 target and continued institutional interest.

TXG: Q4 Guidance And 2026 Outlook Will Likely Pressure Rich Sentiment

Analysts have raised their fair value estimate for 10x Genomics from US$9.00 to US$14.00, citing higher assumed revenue growth, a richer future P/E multiple, and recent Street research that highlights an increased price target in the life science tools space. Analyst Commentary Recent research in the life science tools space has highlighted a cautious tone around near term expectations for 10x Genomics, even as some price targets have been adjusted.

TXG: ARK Buying And Platform Advances Will Shape Future Risk Reward Balance

Analysts have raised their price target on 10x Genomics by about 5 percent to reflect a modestly higher fair value estimate of approximately 17.36 dollars per share. This change is supported by slightly improved long term margin expectations and renewed institutional buying interest highlighted by recent ARK Investment purchases.

TXG: ARK Buying And Product Advances Will Shape Balanced Risk Reward Outlook

Analysts have nudged their price target for 10x Genomics slightly higher, from approximately 16.36 dollars to 16.57 dollars, citing incremental improvements in long term growth assumptions and renewed institutional interest following sizable recent share purchases. Analyst Commentary Analyst reaction to the latest moves in 10x Genomics stock has been mixed, with many highlighting both the opportunities created by recent institutional buying and the ongoing execution risks that could affect the company’s valuation trajectory.

TXG: ARK Share Purchase Will Not Offset Persistent Market Pressure

Analysts have modestly raised their fair value estimate for 10x Genomics from $15.86 to $16.36 per share. This change reflects expectations of improved revenue growth, a resilient market position, and support from recent institutional investment activity, despite ongoing macroeconomic headwinds.

There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump

Nov 14
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump

TXG: Institutional Interest And New Assay Expected To Influence Future Performance

Analysts have increased their price target for 10x Genomics from $15.08 to $15.86 per share. They cite improvements in revenue growth and profit margin as key factors behind the upward revision.

Advanced Genomics Tools Will Shape Future Precision Medicine

Despite a decline in consensus revenue growth forecasts, a rising future P/E suggests increased optimism for profitability or valuation, leading to a higher analyst price target for 10x Genomics. What's in the News 10x Genomics guided Q3 2025 revenue to $140–$144 million, noting an impact from $4.0 million in China customer purchases pulled forward due to anticipated tariff changes.

Revenues Not Telling The Story For 10x Genomics, Inc. (NASDAQ:TXG) After Shares Rise 31%

Jun 20
Revenues Not Telling The Story For 10x Genomics, Inc. (NASDAQ:TXG) After Shares Rise 31%

Shareholders May Be Wary Of Increasing 10x Genomics, Inc.'s (NASDAQ:TXG) CEO Compensation Package

May 27
Shareholders May Be Wary Of Increasing 10x Genomics, Inc.'s (NASDAQ:TXG) CEO Compensation Package

Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96

May 14
Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96

Positive Sentiment Still Eludes 10x Genomics, Inc. (NASDAQ:TXG) Following 29% Share Price Slump

Apr 11
Positive Sentiment Still Eludes 10x Genomics, Inc. (NASDAQ:TXG) Following 29% Share Price Slump

We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth

Mar 26
We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth
User avatar

Chan Zuckerberg Initiative Partnership Will Drive Future Demand

Strategic introduction of lower-priced products and sales reorganization are poised to drive volume growth and enhance market share in biopharma and academia.

10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Feb 21
10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

10x Genomics: Struggling Amid Operational Challenges

Jan 06

Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

Nov 01
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

10x Genomics: Deciphering The Preliminary Q3 Earnings

Oct 12

The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

Oct 11
The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

10x Genomics Is Still A Long Way From Profitability

Oct 03

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Sep 09
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

Aug 10
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

10x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead

Jul 10

10x Genomics: Sticking To The Plan To Avoid The Falling The Knife

Jun 21

Analyse CEO-vergoeding

Hoe is Serge Saxonov's beloning veranderd ten opzichte van 10x Genomics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Dec 31 2025US$6mUS$674k

-US$44m

Sep 30 2025n/an/a

-US$76m

Jun 30 2025n/an/a

-US$85m

Mar 31 2025n/an/a

-US$157m

Dec 31 2024US$8mUS$625k

-US$183m

Sep 30 2024n/an/a

-US$183m

Jun 30 2024n/an/a

-US$240m

Mar 31 2024n/an/a

-US$264m

Dec 31 2023US$8mUS$545k

-US$255m

Sep 30 2023n/an/a

-US$223m

Jun 30 2023n/an/a

-US$172m

Mar 31 2023n/an/a

-US$174m

Dec 31 2022US$19mUS$504k

-US$166m

Sep 30 2022n/an/a

-US$167m

Jun 30 2022n/an/a

-US$142m

Mar 31 2022n/an/a

-US$89m

Dec 31 2021US$12mUS$430k

-US$58m

Sep 30 2021n/an/a

-US$455m

Jun 30 2021n/an/a

-US$504m

Mar 31 2021n/an/a

-US$533m

Dec 31 2020US$11mUS$400k

-US$543m

Sep 30 2020n/an/a

-US$134m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$2mUS$394k

-US$31m

Compensatie versus markt: De totale vergoeding ($USD 6.33M ) Serge } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.19M ).

Compensatie versus inkomsten: De vergoeding van Serge is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Serge Saxonov (48 yo)

13.8yrs
Tenure
US$6,329,244
Compensatie

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Serge Saxonov
Co-Founder13.8yrsUS$6.33m3.26%
$ 91.7m
Benjamin Hindson
Co-Founder13.8yrsUS$2.60m2.42%
$ 68.1m
Adam Taich
CFO, Treasurer1.8yrsUS$2.23m0.057%
$ 1.6m
Jim Goodrich
Chief of Global Operations2.3yrsgeen gegevensgeen gegevens
Michael Schnall-Levin
Founding Scientist & CTO4.3yrsgeen gegevensgeen gegevens
Cassie Corneau
Manager of Investor Relations & Strategic Financeno datageen gegevensgeen gegevens
Randy Wu
General Counsel and Secretaryless than a yeargeen gegevensgeen gegevens
Mennah Moustafa
Chief Commercial Officer1.8yrsgeen gegevensgeen gegevens
Jens Durruthy
Associate Director of Product Managementno datageen gegevensgeen gegevens
2.3yrs
Gemiddelde duur
50yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van TXG wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Serge Saxonov
Co-Founder13.8yrsUS$6.33m3.26%
$ 91.7m
Benjamin Hindson
Co-Founder13.8yrsUS$2.60m2.42%
$ 68.1m
Kimberly Popovits
Independent Director6.2yrsUS$216.32k0.010%
$ 292.4k
John Stuelpnagel
Independent Chairman12.8yrsUS$283.41k1.93%
$ 54.5m
Shehnaaz Suliman
Independent Director6.8yrsUS$210.99k0.010%
$ 292.4k
Alan Mateo
Independent Director1.9yrsUS$208.27k0.031%
$ 882.0k
Sridhar Kosaraju
Independent Director7.1yrsUS$223.32k0.044%
$ 1.2m
Sarah Polonius-Teichmann
Independent Director1.8yrsUS$198.32kgeen gegevens
6.9yrs
Gemiddelde duur
51.5yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TXG wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.9 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/01 02:09
Aandelenkoers aan het einde van de dag2026/05/01 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

10x Genomics, Inc. wordt gevolgd door 22 analisten. 15 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Luke SergottBarclays
Michael RyskinBofA Global Research
Kyle MiksonCanaccord Genuity